妥泰联合丙戊酸钠治疗96例难治性癫痫临床效果  

Clinical Effect of Topamax and Valproate in the Treatment of 96 Patients with Refractory Epilepsy

作　　者：王磊[1] 陈建权[1] 王晋朝[1] 田军彪[2] 

机构地区：[1]唐山市玉田县医院内五科,玉田064100 [2]河北省中医院脑病科,石家庄050011

出　　处：《中国医药导刊》2015年第9期933-934,共2页Chinese Journal of Medicinal Guide

摘　　要：目的：研究妥泰联合丙戊酸钠治疗难治性癫痫的临床应用价值。方法：回顾性分析2009年9月~2014年1月我院收治的难治性癫痫患者96例,随机将全部患者分成两组,对照组对患者采取妥泰进行治疗,研究组对患者采取妥泰联合丙戊酸钠共同治疗,对研究组与对照组患者之间的相关治疗效果和不良反应给予对比分析。结果：总有效率方面,对照组和研究组分别为68.8%和91.6%,研究组显著优于对照组,差异有显著性（P〈0.05）。研究组不良反应发生率为6.25%,对照组不良反应发生率为22.91%,研究组不良反应发生率显著低于对照组,差异有显著性（P〈0.05）。结论：难治性癫痫采取妥泰联合丙戊酸钠治疗,疗效显著,并且不良反应较低。Objective： To study the effect of topiramate combined with sodium valproate in the treatment of refractory epilepsy in clinical application.Methods：Sep 2009-Jan2014 in hospital patients suffering from intractable epilepsy received a total of 96 cases were randomly divided into study group and the control group, the control group of patients taking topiramate for treatment, research group together to take topamax joint valproate therapy in patients with treatment-related effects on the study group and the control group were given between adverse reactions and analyzed.Results：The total efficiency of the control group and study group were 68.8% and 91.6%, the study group was significantly better than the control group, the difference was significant （P〈0.05）;The incidence of adverse events in the study group was significantly lower than the control group （P〈0.05）. Conclusion：Take topiramate combined with sodium valproate in treatment of intractable epilepsy, remarkable curative effect and adverse reaction is low.

关 键 词：妥泰 丙戊酸钠 难治性癫痫 

分 类 号：R742.1[医药卫生—神经病学与精神病学]